Previous 10 | Next 10 |
home / stock / oryzf / oryzf news
Oryzon Genomics S.A. (OTCPK:ORYZF): Q2 GAAP EPS of $0.02. Cash and equivalents of $40.08M. Press Release For further details see: Oryzon Genomics S.A. reports Q2 results
MADRID, Spain and CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for...
Clinical Trial Application approved by Spanish Drug Agency Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Second Phase IIb study of vafidemstat in CNS disorders MADRID, Spain and CAMBRIDGE, Ma...
Vafidemstat was safe and well tolerated Confirmed anti-inflammatory activity of vafidemstat Vafidemstat reduced exacerbated CD4+ T cell activation and inflammatory cytokine release Fast recovery of patients observed in both arms MADRID, Spain and CAMBRIDG...
NewYorkBIO and NYSE’s Emerging Biotech Company Showcase Spring European Virtual MidCap Event 31 st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2021) Epigenetic Therapeutic Target Summit MADRID, Spain a...
Recruitment ongoing in Europe Primary objectives: to assess the effect of vafidemstat to address agitation and aggression and to improve overall disease MADRID, Spain and CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES01677330...
Robust signals of clinical efficacy, with ORR of 83%, of which 67% are CR/CRi Five patients with responses longer than 1 year Longest remission 858 days, still ongoing Rapid onset of responses (TTR 29 days) Iadademstat and azacitidine combination shows ...
BioEquity Europe Digital Oxford Global’s Online Drug Discovery Week Jefferies Virtual Healthcare Conference 2021 Precision in Drug Discovery & Preclinical Virtual Summit European Hematology Association (EHA) 2021 Congress BIO Inter...
Oryzon Genomics S.A. (ORYZF): Q1 GAAP EPS of -$0.04.Cash, cash equivalents and marketable securities totaled $45.2 million as of March 31, 2021, compared to $32.1 million as of March 31, 2020.Press Release For further details see: Oryzon Genomics S.A. reports Q1 results
MADRID, Spain and CAMBRIDGE, Ma., May 07, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for th...
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a c...
Selected for oral presentation Conference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity A third cohort is ongoing following FDA’s OPTIMUS guidance MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon G...